Article Text

THU0552 Compliance to colchicine treatment in familial meditterranean fever related amyloidosis
  1. B Yurttas1,
  2. S Ugurlu2,
  3. H Ozdogan2
  1. 1Department of Internal Medicine
  2. 2Department of Internal Medicine, Division of Rheumatology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey


Objectives To assess the colchicine compliance in patients diagnosed with Familial Mediterrenean Fever (FMF) related amyloidosis in our center.

Methods Fourty one patients (18 male/23 female) were questioned with regards to colchicine compliance by using retrospective scanning of patient data.

Results The mean age at the symptomatic onset of FMF was 7.13±5.24 years. The mean age at the time of the FMF diagnosis was 21.21±14.85 years. The mean age at the initiation of colchicine treatment was 21.42±14.75 years and the mean age at time of the diagnosis of amyloidosis was found 29.57±12.14 years. Mean duration of the disease was 31.702±11.84 years and the duration of delayed diagnosis was 14.35±13.84 years. Maximum dose of colchicine was 2,103±0,673 mg/day. Compliance of colchicine treatment was poor in FMF related amyloidosis during their follow-up (11/25, %44), rates of skipped doses were also high (17/25, %68). Compliance rates were high in patients in whom FMF and amyloidosis were diagnosed simultaneously (12/13, %93), rates of skipped doses were also low (2/13, %14). One of the patients diagnosed with FMF after the diagnosis of amyloidosis was compliant, two of them were non-compliant; with regards to skipping doses, two patients were found to be compliant and therefore never skipped doses while one was skipping doses. The compliance to colchicine was high in all FMF patients once amyloidosis was evident (31/41, %75), and rates of skipped doses were also low (12/41, %30). In five FMF patients, amyloidosis was observed despite their compliance to treatment.

Conclusions The overall delay of diagnosis in FMF patients with amyloidosis was found to be high. Particularly the FMF patients who were diagnosed with amyloidosis during their follow up were found to have lower rates of compliance. There were also a group of patients who were diagnosed with amyloidosis despite adequate and convenient colchicine treatment. It was emphasized that not only the early diagnosis and adequate treatment, but also the close follow up is important in managing FMF patients.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.